A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine

A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine

We examined the safety, immunogenicity and efficacy of a prime-boost vaccination regime involving two poxvirus malaria subunit vaccines, FP9-PP and MVA-PP, expressing the same polyprotein consisting of six pre-erythrocytic antigens from Plasmodium falciparum.

Bibliographic Details
Main Authors: Porter, David W., Thompson, Fiona M., Berthoud, Tamara K., Hutchings, Claire L., Andrews, Laura, Biswas, Sumi, Poulton, Ian, Prieur, Eric, Correa, Simon, Rowland, Rosalind, Lang, Trudie, Williams, Jackie, Gilbert, Sarah C., Sinden, Robert E., Todryk, Stephen, Hill, Adrian V.S.
Format: Online
Language:English
Published: Elsevier Science 2011
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195259/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195259/

Similar Items